scholarly journals Gingival health in children in the different phases of acute lymphoblastic leukemia

2019 ◽  
Vol 32 (3) ◽  
pp. 134-137 ◽  
Author(s):  
Luidmyla F. Kaskova ◽  
Nataliia V. Yanko ◽  
Irena Y. Vashchenko

Abstract Acute lymphoblastic leukemia (ALL), the most common type of leukemia in children, has diverse oral cavity complications. While periodontal alterations in such patients are widely known, there were no studies evaluating gingival health from the time of diagnosis to the remission phase. In our study, we, therefore, analysed the frequency of periodontal diseases and the gingival indices in the different phases of ALL in children. Children aged 7-15 years were involved into the cross-sectional study. Therein, 160 children with ALL were divided into three groups: L1 – 50 children examined before the initiation phase, L2 – 50 children examined after 1 month of the chemotherapy, L3 – 60 children examined in permanent hematologic remission. The control (HC) included 150 healthy children. The L1, L2 and L3 groups had significantly worse gingival indices and frequency of gingivitis than the HC group (p < 0.0001). Frequency of gingivitis increased from before the initiation to the remission phase, but significantly only in 7-11 year-old children (p = 0.0004). Gingival indices increased after 1 month of chemotherapy (p < 0.0001), but decreased in the permanent remission phase (p < 0.0001). Our study stresses the need for children with ALL to not only require prevention courses before the initiation and during the chemotherapy phases, but also in the permanent remission phase to minimize the long-term impact of leukemia treatment on gingival health.

2021 ◽  
pp. 1-11
Author(s):  
Stephane Lepretre ◽  
Chantal Touboul ◽  
Alain Flinois ◽  
Lucie Kutikova ◽  
Christina Giannopoulou ◽  
...  

2009 ◽  
Vol 52 (1) ◽  
pp. 33-38 ◽  
Author(s):  
Kara M. Kelly ◽  
John C. Thornton ◽  
Deborah Hughes ◽  
Ifeyinwa Osunkwo ◽  
Michael Weiner ◽  
...  

2020 ◽  
Vol 20 (8) ◽  
pp. e523-e528
Author(s):  
Wellington F. da Silva ◽  
Ires H.B. Massaut ◽  
Rodrigo M. Bendlin ◽  
Lidiane I. Rosa ◽  
Elvira D.R.P. Velloso ◽  
...  

2015 ◽  
Vol 15 (1) ◽  
pp. e7-e14 ◽  
Author(s):  
Edilson Diogenes Pinheiro Junior ◽  
Luis Fernando Pracchia ◽  
Beatriz Beitler de Mauriño ◽  
Gracia Aparecida Martinez ◽  
Pedro Enrique Dorlhiac-Llacer ◽  
...  

Author(s):  
NUR MELANI SARI ◽  
NABILLA PUTRI OSSEVA ◽  
NUR SURYAWAN

Objective: The objective of the study was to determine and describe the characteristics of allergic reactions to Escherichia coli-Asparaginase (E. coli-ASP). Methods: This cross-sectional study was performed at Hasan Sadikin Bandung General Hospital on acute lymphoblastic leukemia patients diagnosed from January 1, 2018, to August 31, 2019, confirmed by bone marrow examination. Data were extracted from Bandung Online Pediatric Cancer Registry, medical records, protocol therapy documents, and interview with patient’s guardian. Results: Out of 68 patients, 26 patients (37.6%) were allergic to E. coli-ASP. Twenty-two patients with recorded manifestation’s data evoked 35 symptoms and graded according to common terminology criteria for adverse event v3.0., fever, and urticaria are the most frequent manifestation. While Grade 2 and Grade 3 are the most often developed allergic reaction, patients with age range from 1 to 14 years, male and high risk is mainly allergic. Conclusion: Allergic rate to E. coli-ASP at Hasan Sadikin General Hospital is 37.6%. The most frequent manifestation is fever and urticaria (20%, respectively), Grades 2 and 3 (32%, respectively), and emerged mostly after administration of fourth dose E. coli-ASP (26.9%). Despite the characteristic differences between allergic and non-allergic group, it is not statistically significant.


2017 ◽  
Vol 39 (3) ◽  
pp. 202-209 ◽  
Author(s):  
Gabriela Galindo-Rodríguez ◽  
José C. Jaime-Pérez ◽  
Mario C. Salinas-Carmona ◽  
Sandra N. González-Díaz ◽  
Ángeles Castro-Corona ◽  
...  

2014 ◽  
Vol 54 (6) ◽  
pp. 372 ◽  
Author(s):  
Andry Juliansen ◽  
Murti Andriastuti ◽  
Sudung Pardede ◽  
Rini Sekartini

Background Hypertension is a rarely recognized complicationof acute lymphoblastic leukemia (ALL). The incidence ofhypertension in ALL patients in Indonesia remains unknown,but the most common risk factors are corticosteroid use duringinduction-phase chemotherapy and renal leukemic infiltration.Objective To determine the incidence of hypertension in childrenwith ALL, and to assess for associations of high-dose corticosteroids,renal infiltration, and hyperleukocytosis to hypertension.Methods This was a cross-sectional study involving 100 childrenaged 2-18 years. Subjects were newly diagnosed ALL patients andthose underwent induction-phase chemotherapy in the PediatricWard or Outpatient Clinic at Cipto Mangunkusumo or DharmaisHospitals.Results Hypertension occurred in 6 (10%) of 60 newly diagnosedALL patients and 8 (20%) of 40 patients who had receivedhigh-dose corticosteroids, but the difference was not statisticallysignificant (OR=2.25; 95%CI 0.72 to 7.07; P=0.239). Hypertensionwas reported in 8 of 29 subjects who received dexamethasone,but in none of the subjects who received prednisone. However, thedifference in these subgroups was also not statistically significant.Renal enlargement was found in 1 of 14 hypertensive patients, butit was not associated with hypertension (OR=0.80; 95%CI 0.52to 1.24; P=0.417). Hyperleukocytosis was also not associated withhypertension (OR= 0.79; 95% CI 0.20 to 3.11; P=1.000).Conclusion The incidence of hypertension in ALL patients was14%. Hypertension is not associated with renal infiltration orhyperleukocytosis. Furthermore, hypertension is not associatedwith corticosteroid dose, though is found only in subjects whoreceive dexamethasone. [Paediatr Indones. 2014;54:372-6.].


Sign in / Sign up

Export Citation Format

Share Document